ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alirocumab

Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.

Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 24, 201548 company-led studies, 1 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only300 open or runningphase 4since Dec 24, 2015Feb 1, 2011none ahead
Regeneron Pharmaceuticalsits history only161 open or runningphase 4since Oct 28, 2016Nov 20, 2009Dec 29, 2026phase 2 · NCT07477704
Kobe University20 open or runningphase 4since May 7, 2018May 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kobe University only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2018First studies: 2 phase 4 studies in Coronary Artery DiseaseFirst studyNCT03552432, NCT03529253

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 2 Kobe University leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03552432Coronary Artery Disease · Japan4UNKNOWNSep 30, 202024
NCT03529253Coronary Artery Disease · Japan4UNKNOWNSep 30, 202030

How it is read

Names in the registry

  • “Alirocumab”, 28 entries
  • “alirocumab SAR236553 (REGN727)”, 8 entries
  • “Alirocumab SAR236553 (REGN727)”, 2 entries
  • “alirocumab”, 2 entries
  • “REGN727”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.